Engineered bacteria launch and control an oncolytic virus
- PMID: 40817284
- DOI: 10.1038/s41551-025-01476-8
Engineered bacteria launch and control an oncolytic virus
Abstract
The ability of bacteria and viruses to selectively replicate in tumours has led to synthetic engineering of new microbial therapies. Here we design a cooperative strategy whereby Salmonella typhimurium bacteria transcribe and deliver the Senecavirus A RNA genome inside host cells, launching a potent oncolytic viral infection. 'Encapsidated' by bacteria, the viral genome can further bypass circulating antiviral antibodies to reach the tumour and initiate replication and spread within immune mice. Finally, we engineer the virus to require a bacterially delivered protease to achieve virion maturation, demonstrating bacterial control over the virus. Together, we refer to this platform as 'CAPPSID' for Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery. This work extends bacterially delivered therapeutics to viral genomes, and shows how a consortium of microbes can achieve a cooperative aim.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: Z.S.S., J.P. and T.D. have filed provisional patent applications (US Patent application nos. 63/471,863, 63/541,079 and 63/610,152 on 8 June 2023, 28 September 2023 and 14 December 2023) with the US Patent and Trademark Office related to this work and have also filed PCT/US2024/032961 on 7 June 2024 with the World Intellectual Property Organization. The other authors declare no competing interests.
Update of
-
Engineered bacteria launch and control an oncolytic virus.bioRxiv [Preprint]. 2025 Jan 7:2023.09.28.559873. doi: 10.1101/2023.09.28.559873. bioRxiv. 2025. Update in: Nat Biomed Eng. 2025 Aug 15. doi: 10.1038/s41551-025-01476-8. PMID: 37808855 Free PMC article. Updated. Preprint.
References
LinkOut - more resources
Full Text Sources